We are live on ! Find out more
MG

Meditor Group Portfolio holdings

AUM $48.1M
1-Year Est. Return 38.67%
This Fund
S&P 500
This Quarter Est. Return
+12.95%
1 Year Est. Return
+38.67%
3 Year Est. Return
+41.15%
5 Year Est. Return
+72.2%
10 Year Est. Return
+1,065.64%
AUM
$126M
AUM Growth
-$22.4M
Cap. Flow
-$21.1M
Cap. Flow %
-16.82%
Top 10 Hldgs %
100%
Holding
4
New
Increased
Reduced
2
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$20.8M
2
ESPR
Esperion Therapeutics
ESPR
+$340K

Sector Composition

Rank Sector Weight
1 Healthcare 89.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.9B
$105M 83.69%
5,412,900
-1,192,286
-18% -$20.8M
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
$7M 5.58%
4,402,973
-65,862
-1% -$340K
EPI icon
3
WisdomTree India Earnings Fund ETF
EPI
$2.02B
$6.74M 5.37%
213,800
INDA icon
4
iShares MSCI India ETF
INDA
$6.71B
$6.74M 5.37%
171,200

Similar funds

Meditor Group's Q1 2023 Portfolio in Review

As of Q1 2023, Meditor Group held 4 positions worth $126M, down 15% from $148M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Meditor Group withdrew a net $21.1M in Q1 2023, reducing 2 holdings. Its largest reduction was Exelixis, cutting an estimated $20.8M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

  • Meditor Group's biggest Q1 2023 reduction was Exelixis, cutting an estimated $20.8M.
  • Meditor Group's ten largest holdings make up 100% of its $126M portfolio in Q1 2023.
  • Meditor Group opened 0 new positions and closed 0 in Q1 2023.
  • Meditor Group's portfolio value fell 15% quarter-over-quarter to $126M.

Based on Meditor Group's 13F filing for Q1 2023, filed 10 Apr 2023.